2018
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
Cardoso F, Bartlett J, Slaets L, van Deurzen C, van Leeuwen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schröder C, Martens J, Bayani J, van Asperen C, Murray M, Hudis C, Middleton L, Vermeij J, Punie K, Fraser J, Nowaczyk M, Rubio I, Aebi S, Kelly C, Ruddy K, Winer E, Nilsson C, Dal Lago L, Korde L, Benstead K, Bogler O, Goulioti T, Peric A, Litière S, Aalders K, Poncet C, Tryfonidis K, Giordano S. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Annals Of Oncology 2018, 29: 405-417. PMID: 29092024, PMCID: PMC5834077, DOI: 10.1093/annonc/mdx651.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalMale breast cancerAdjuvant endocrine therapyBreast cancerEndocrine therapySentinel lymph node biopsyLymph node biopsyBreast cancer programFemale breast cancerDuctal invasive carcinomaBC mortalityIHC subtypesIHC surrogatesAdjuvant radiotherapyM1 patientsMetastatic diseaseMedian ageCentral pathologyM0 tumorsM0 casesProgesterone receptorCancer programsInvasive carcinomaKi67 expressionAndrogen receptor
2012
The natural history of hormone receptor-positive breast cancer.
Lim E, Metzger-Filho O, Winer EP. The natural history of hormone receptor-positive breast cancer. Oncology 2012, 26: 688-94, 696. PMID: 22957400.Peer-Reviewed Original ResearchConceptsBreast cancerEstrogen receptorLate relapseProgesterone receptorHormone receptor-positive breast cancerAdjuvant anti-estrogen therapyHR-positive breast cancerReceptor-positive breast cancerNatural historyHormone receptorsAnti-estrogen therapyLong natural historyPredictors of responseBreast cancer subtypesHuman breast tumorsSignificant clinical challengePatient tumor samplesTranslational research strategiesCurrent clinical strategiesAntiestrogen therapyRelapse patternsPreclinical modelsClinical challengeTreatment resistanceTumor relapseClinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network
Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong Y, Blayney DW, Niland JC, Winer EP, Weeks JC. Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network. Cancer 2012, 118: 5463-5472. PMID: 22544643, PMCID: PMC3611659, DOI: 10.1002/cncr.27581.Peer-Reviewed Original ResearchConceptsHuman epidermal growth factor receptor 2Triple-negative tumorsHR-positive/HER2-negative tumorsHER2-negative tumorsTriple-negative subtypePatterns of recurrenceEstrogen receptorProgesterone receptorClinicopathologic featuresBreast cancerNational Comprehensive Cancer Network centersNational Comprehensive Cancer NetworkHigher body mass indexEpidermal growth factor receptor 2Triple-negative breast cancerLymph node involvementComprehensive Cancer NetworkGrowth factor receptor 2Triple-negative cancersRisk of deathBody mass indexAbnormal screening mammogramBreast cancer subtypesHigher tumor classificationFactor receptor 2
2011
P1-08-05: Age and Survival in Women with Early Stage Breast Cancer: An Analysis Controlling for Tumor Subtype.
Partridge A, Hughes M, Ottesen R, Wong Y, Edge S, Theriault R, Blayney D, Niland J, Winer E, Weeks J, Tamimi R. P1-08-05: Age and Survival in Women with Early Stage Breast Cancer: An Analysis Controlling for Tumor Subtype. Cancer Research 2011, 71: p1-08-05-p1-08-05. DOI: 10.1158/0008-5472.sabcs11-p1-08-05.Peer-Reviewed Original ResearchMultivariate Cox proportional hazards modelEarly-stage breast cancerCox proportional hazards modelStage breast cancerProportional hazards modelBreast cancerEstrogen receptorYoung womenProgesterone receptorStratified analysisOlder womenHazards modelTumor subtypesYounger ageBreast cancer-specific survivalHER-2/neu statusCancer-specific survivalER-positive diseaseIndependent risk factorEarly breast cancerER-negative diseaseAge 40 yearsBreast cancer recurrenceEfficacy of therapyBreast cancer biologyAdjuvant chemotherapy in luminal breast cancers
Lim E, Winer EP. Adjuvant chemotherapy in luminal breast cancers. The Breast 2011, 20: s128-s131. PMID: 22015279, DOI: 10.1016/s0960-9776(11)70309-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsAntineoplastic Agents, HormonalBiomarkersBreast NeoplasmsChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansMiddle AgedNeoplasm StagingNeoplasms, Hormone-DependentPrognosisRandomized Controlled Trials as TopicReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsAdjuvant endocrine therapyLuminal breast cancerEndocrine therapyBreast cancerEstrogen receptorAdjuvant chemotherapyProgesterone receptorHER2-negative breast cancerER-positive breast tumorsAddition of chemotherapyER-positive diseaseER-positive tumorsUse of chemotherapySubset of patientsSubgroup of patientsER-negative tumorsAdditional therapyCytotoxic chemotherapyEndocrine sensitivityClinicians' estimationTherapeutic responseFavorable outcomeCurrent biomarkersChemotherapyBreast tumors
2009
Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN)
Lin N, Vanderplas A, Hughes M, Theriault R, Edge S, Wong Y, Blayney D, Niland J, Winer E, Weeks J. Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). Journal Of Clinical Oncology 2009, 27: 543-543. DOI: 10.1200/jco.2009.27.15_suppl.543.Peer-Reviewed Original ResearchNational Comprehensive Cancer NetworkSite of recurrenceBreast cancer subtypesClinicopathological featuresProgesterone receptorEstrogen receptorStage ICancer subtypesInvasive ductal histologyExtensive intraductal componentComprehensive Cancer NetworkPatterns of recurrenceFuture clinical trialsMultiple breast cancer subtypesStandard immunohistochemical markersDuctal histologyLymphovascular invasionNode positivityIntraductal componentHER2 statusTN tumorsClinical trialsBreast cancerSubtype distributionImmunohistochemical markers
2006
The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer
Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer. Cancer 2006, 106: 2576-2582. PMID: 16703595, DOI: 10.1002/cncr.21919.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsBreast NeoplasmsChemotherapy, AdjuvantCross-Over StudiesDecision Support TechniquesDisease-Free SurvivalDrug Administration ScheduleFemaleHumansMarkov ChainsMiddle AgedModels, StatisticalModels, TheoreticalNeoplasm StagingOdds RatioPostmenopauseRandomized Controlled Trials as TopicReceptors, ProgesteroneTamoxifenTime FactorsTreatment OutcomeConceptsDisease-free survivalAromatase inhibitorsProgesterone receptorEstrogen receptorOptimal adjuvant endocrine therapyEarly-stage breast cancerAdjuvant endocrine therapyNode-positive groupProgesterone receptor statusRandomized clinical trialsSequential treatmentBreast cancer tumorsAI monotherapyAI therapyBiologic subsetsDFS ratesAdjuvant therapyEndocrine therapyPostmenopausal patientsPostmenopausal womenSequential therapyUpfront treatmentLymph nodesReceptor statusPR expression